Skip to main content

Table 6 Binary and multivariable logistic regression of factors associated with adherence to H. pylori eradication therapy in the hospitals in Hawassa city, February–June 2023 (n = 291)

From: Prevalence of Helicobacter pylori infection and effectiveness of first-line triple eradication therapy among dyspeptic patients at hospitals in Hawassa City, Ethiopia: a cross-sectional follow-up study

Variable

Category

Adherence

COR (CI: 95%)

P-value

AOR (CI: 95%)

P-value

Adhered

Not-adhered

Sex

Male

77

17

  

–

–

Female

153

44

1.30 (0.70, 2.43)

0.41

–

–

Age (years)

18–24

60

19

–

–

–

–

25–34

86

19

0.60 (0.18, 1.97)

0.40

–

–

35–44

41

11

0.86 (0.26, 2.80)

0.80

–

–

45–54

22

8

0.71 (0.20, 2.50)

0.59

–

–

> 54

21

4

0.52 (0.14, 2.00)

0.34

–

–

Residence

Rural

122

40

–

–

–

–

Urban

108

21

1.69 (0.93, 3.03)

0.08

0.49 (0.23, 1.01)

0.52

Educational status

Illiterate

28

6

–

–

–

–

Primary school

25

7

1.47 (0.56, 3.84)

0.43

0.77 (0.21, 2.85)

0.69

Secondary school

69

14

1.12 (0.45, 2.83)

0.80

1.48 (0.48, 4.63)

0.50

College and above

108

34

1.55 (0.78, 3.10)

0.21

0.85 (0.30, 2.48)

0.77

History of gastritis

No

94

24

–

–

–

–

Yes

136

37

1.066 (0.60, 1.90)

0.83

–

–

History of H. pylori status

Not known

102

27

–

–

–

–

Positive

40

7

1.16 (0.63, 2.12)

0.63

0.92 (0.46, 1.81)

0.83

Negative

88

27

1.753 (0.70, 4.36)

0.23

1.79 (0.69, 4.69)

0.23

History of eradication therapy

No

205

56

–

–

–

–

Yes

25

5

0.73 (0.27, 2.00)

0.54

–

–

Duration of illness

Less than a month

77

15

–

–

–

–

More than a month

153

46

1.54 (0.81, 2.94)

0.19

0.54 (0.27, 1.08)

0.08

History of other illnesses

No

144

38

–

–

–

–

Yes

86

23

1.01 (0.57, 1.81)

0.97

–

–

History of alcohol intake

No

37

9

–

–

–

–

Yes

193

52

1.11 (0.50, 2.44)

0.80

–

–

History traditional medicine use

No

199

57

–

–

–

–

Yes

31

44

0.45 (0.15, 1.33)

0.15

2.35 (0.74, 7.45)

0.15

Eradication regimen used

OAC for 14-days

217

54

–

–

–

–

OAC for 10-days

13

7

2.16 (0.82, 5.68)

0.12

0.40 (0.14, 1.12)

0.08

Regimen completeness

Complete

163

44

–

–

–

–

Incomplete

67

17

0.94 (0.50, 1.76)

0.85

–

–

Adverse effect self-report

Present

106

37

–

–

–

–

Absent

124

24

1.80 (1.01, 3.21)

0.04

2.45 (1.29, 4.62)

0.006